An observational study in Lung Diseases, sponsored by University Hospital Olomouc. Recruiting at 1 site in Czechia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-27.
Sponsored by University Hospital Olomouc · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Lung Diseases with a site in Czechia — 10 open to participants now, 14 under way, 7 of them phase 3. Lung Diseases · Czechia.
Among the 29 studies in Lung Diseases with a site in Czechia, this one is one of 4 that started in 2025, is one of 2 observational ones, reaches primary completion later than 9 of the 13 other live ones, and was the 27th registered.
1,159 studies on the registry are indexed under Lung Diseases; 181 are open to participants now.
Browse Lung Diseases studies →10 of the 29 studies in Lung Diseases with a site in Czechia are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Czechia, United States, Argentina and 15 more countries
Ages 40–75
AstraZeneca · Sites in Czechia, United States, Argentina and 4 more countries
Ages 4–11
Nuvalent Inc. · Sites in Czechia, United States, Argentina and 26 more countries
Ages 18+
Pfizer · Sites in Czechia, United States, Argentina and 12 more countries
Ages 18–75
Pfizer · Sites in Czechia, United States, Argentina and 16 more countries
Ages 12+
A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →
Of the 138 Lung Diseases studies recruiting now, 75 (54%) set no upper age limit and 28 (20%) stop at 75 or younger; 15 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 200 across 315 observational studies indexed under Lung Diseases.
Median enrollment 604 across the 27 interventional studies, 264 across the 2 observational. Of the 15 that completed or were terminated, 10 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 29 have an industry lead sponsor. The 10 most frequent:
University Hospital Olomouc is the lead sponsor of 40 studies on the registry; 13 are open to participants now.
University Hospital Olomouc has 1 study filed under Lung Diseases — fewer than ten, so there is no comparison to draw.
7 of the studies in Lung Diseases with a site in Czechia that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT06977581PfizerA Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma | 2027-03-08 |
Add all 7 to your calendar (.ics) → With an account.
Among the 29 studies in Lung Diseases with a site in Czechia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study titled "The Use of Electrical Impedance Tomography (EIT) in Pulmonary Diseases" investigates the impact of using EIT as a non-invasive method to monitor the distribution of pulmonary ventilation and its relationship to standard spirometry in patients with various lung diseases. The main aim of this study is to investigate new approaches to the assessment of lung status and diagnosis of lung diseases.
Unlike spirometry, which has long been a well-known and important diagnostic tool in pulmonary medicine, and which provides valuable information about the volume and flow of inspired and expired air, EIT provides spatial information about the distribution of ventilation in real time and without the need for active patient cooperation. Research and practice have shown that spirometry is problematic in specific groups of patients, such as patients with tracheostomy or facial palsy. The technology should also enable detection of the disease in its early stages, when treatment is most effective.
300 participants in the experimental group and 100 participants in the control group will receive spirometry and electrical impedance tomography independent examination.
The primary endpoint of the study is to investigate the potential of EIT in respiratory medicine, specifically identifying the relationship between EIT and traditional spirometry. This effort is motivated by the need for novel noninvasive methods for the diagnosis and monitoring of respiratory diseases, especially in patients unable to undergo conventional spirometry, or in case of interventions requiring real-time feedback. The purpose of the research project in relation to these objectives is to bring new possibilities in the field of diagnosis and monitoring of lung diseases through EIT, which could lead to significant improvements in patient care.
Demographic and anthropometric data, including age, sex, body height, body weight, body mass index (BMI), chest circumference, and smoking history will be collected in all participants. These parameters will be used as covariates in the analysis to assess their impact on EIT-derived indicators and to improve normalization of EIT signals.
Additionally, the study aims to develop and validate a machine learning model, particularly a deep neural network, capable of predicting standard spirometric parameters (e.g., FEV1, FVC, PEF) based solely on EIT signals. This could allow for an accurate assessment of dynamic pulmonary volumes in cooperating patients who are unable to undergo conventional spirometry (e.g. patients with tracheostomy).
Patients of the Department of Pulmonary Diseases and Tuberculosis, University hospital Olomouc, and healthy controls.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Signing of an that has been approved by the ethics committee
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults aged 18 years and older Individuals diagnosed with any of the following lung diseases, as these are the primary focus of the study: Chronic obstructive pulmonary disease, Asthma, Pulmonary fibrosis, Pneumonia, Patients with a history of COVID-19 infection showing residual pulmonary findings. Ability to perform spirometry while seated, except for possible participants who are specifically part of a subgroup analysis where inability to perform spirometry is the condition which is studied. Signing of an informed consent that has been approved by the ethics committee
Adults aged 18 years and older Healthy subjects will be enrolled to obtain normal standard values (with normal physical examination and no respiratory symptoms, BMI 18-31 - cause EIT performance can be BMI dependent, Non-smokers or ex-smokers abstinent ≥12 months) Ability to perform spirometry while seated, except for possible participants who are specifically part of a subgroup analysis where inability to perform spirometry is the condition which is studied. Signing of an informed consent that has been approved by the ethics committee
Agreement between EIT-derived FEV1 and spirometry-derived FEV1
Comparison of forced expiratory volume in 1 second predicted from EIT using a trained neural network with direct spirometry measurement. Metric: Mean Absolute Error (MAE), Bland-Altman limits of agreement, Pearson correlation coefficient (r)
Time frame: At baseline visit (single measurement)
Forced Expiratory Volume in One Second (FEV1)
FEV1 represents the volume of air that can be forcibly exhaled in the first second of a forced exhalation Measurements will be performed using calibrated spirometry. FEV1 is a standard measure of pulmonary function. Unit of Measure: Liters
Time frame: At baseline visit (single measurement)
Forced vital capacity (FVC)
FVC represents the largest amount of air that can be forcefully exhaled from maximum inspiration. Unit of Measure: Liters
Time frame: At baseline visit (single measurement)
Peak Expiratory Flow (PEF)
PEF represents the maximum flow achieved during forceful exhalation from maximum inspiration and is a reliable indicator of ventilation adequacy as well as airflow obstruction. Unit of Measure: Liters/minute
Time frame: At baseline visit (single measurement)
Estimated Lung Age (ELA)
ELA is a calculation that estimates the age of a person's lungs based on their lung function, particurarly FEV1 (forced expiratory volume in one second), compared to normal lung function for their chronological age. Secondary objectives include comparison of regional ventilation patterns from EIT with spirometric flow-volume loop abnormalities, assessment of EIT-based estimated lung age, and determination of EIT's ability to track treatment response over time.
Time frame: At baseline visit (single measurement)
Forced Expiratory Volume in Three Seconds (FEV3)
FEV3 represents the volume of air that can be exhaled during the first three seconds of forceful exhalation after maximum inspiration. Unit of Measure: Liters
Time frame: At baseline visit (single measurement)
Forced Expiratory Volume in Six Seconds (FEV6)
FEV6 represents the volume of air that can be exhaled during the first six seconds of forceful exhalation after maximum inspiration Unit of Measure: Liters
Time frame: At baseline visit (single measurement
FEV1/FVC ratio
FEV1/FVC is the ratio of forced expiratory volume in one second to forced vital capacity. Unit of Measure: Percentage
Time frame: At baseline visit (single measurement
Forced Expiratory Flow at 50 % of FVC (FEF50)
FEF50 is the flow rate at the 50% point of the total volume (FVC) exhaled. Unit of Measure: Liters
Time frame: At baseline visit (single measurement
Forced Expiratory Flow at 75 % of FVC (FEF75)
FEF75 is the flow rate at the 75% point of the total volume exhaled. Unit of Measure: Liters
Time frame: At baseline visit (single measurement
Plan to share: Undecided
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Dec 2027, 25 months after the start.
Of 131 non-industry observational studies under Lung Diseases, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 95. This study's planned 25 months is below that.
Counting every sponsor, half of 153 studies reached it within 36 months; a quarter within 15 and three quarters within 84.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital Olomouc